Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): PMS-Brimonidine (02246284). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.
BRIMONIDINE
All products: Limited Use (codes 171, 172, 387)
Other products in the same Health Canada class (S01E) — coverage varies; not interchangeable
- Acetazolamide (Acetazolamide): general benefit, Not a benefit
- Betaxolol (Betoptic S): general benefit
- Levobunolol (Betagan): general benefit
- Methazolamide (Neptazane): general benefit, Not a benefit
- Timolol (Timoptic-XE): general benefit, Not a benefit
- Bimatoprost (Lumigan): limited Use 171, 172, 387, Not a benefit
9 more in the class list below
Alphagan P · DIN 02248151 · 0.15% · Oph Sol
Limited Use — Reason for Use code 171, 172, 387 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 171, 172, 387 required
Write on scriptLU code 171, 172, 387 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 171, 172, 387
Reason for Use code 171
As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 172
As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 387
For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Alphagan P · DIN 02248151
Manufacturer: Allergan Inc.; listing date 2004-11-04
Health Canada: Marketed since 2023-11-28 · brand ALPHAGAN P · ATC S01EA05 BRIMONIDINE · form Solution · route Ophthalmic · ingredients BRIMONIDINE TARTRATE 0.15 %/W/V · company Abbvie corporation · schedule Prescription
Ministry pays: $2.0305 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72483 · Verify on the e-Formulary ↗ (DIN 02248151)
Source record
DIN 02248151: Alphagan P
Raw flags: sec12=Y, sec3=Y
Item: 523600107; group id 614; item number 1580; lccId 00082; manufacturer id ALL
Source form: Oph Sol; strength: 0.15%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $2.6017; ministry $2.0305
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248151
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72483
Interchangeable products
Brimonidine P · DIN 02301334 · $2.0305
Shortage status: resolved shortage (ended 2026-09-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248151
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Brimonidine P · DIN 02301334 · 0.15% · Oph Sol
Limited Use — Reason for Use code 171, 172, 387 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 171, 172, 387 required
Write on scriptLU code 171, 172, 387 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 171, 172, 387
Reason for Use code 171
As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 172
As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 387
For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Brimonidine P · DIN 02301334
Manufacturer: A A Pharma Inc.; listing date 2008-10-01
Health Canada: Marketed since 2021-10-20 · brand BRIMONIDINE P · ATC S01EA05 BRIMONIDINE · form Solution · route Ophthalmic · ingredients BRIMONIDINE TARTRATE 0.15 %/W/V · company Aa pharma inc · schedule Prescription
Brimonidine P: Formulary list price $2.0305/unit (unit not stated in source; not the patient's cost)
Ministry pays: $2.0305 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78666 · Verify on the e-Formulary ↗ (DIN 02301334)
Source record
DIN 02301334: Brimonidine P
Raw flags: sec12=Y, sec3=Y
Item: 523600107; group id 614; item number 1580; lccId 00082; manufacturer id AAP
Source form: Oph Sol; strength: 0.15%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $2.0305; ministry $2.0305
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02301334
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78666
Interchangeable products
Alphagan P · DIN 02248151 · $2.0305
Shortage status: active shortage (reported 2026-09-08, estimated to end 2026-09-25, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02301334
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Alphagan · DIN 02236876 · 0.2% · Oph Sol
Limited Use — Reason for Use code 171, 172, 387 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 171, 172, 387 required
Write on scriptLU code 171, 172, 387 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 171, 172, 387
Reason for Use code 171
As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 172
As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 387
For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Alphagan · DIN 02236876
Manufacturer: Allergan Inc.; listing date 1998-12-31
Health Canada: Marketed since 2024-03-27 · brand ALPHAGAN · ATC S01EA05 BRIMONIDINE · form Solution · route Ophthalmic · ingredients BRIMONIDINE TARTRATE 0.2 %/W/V · company Abbvie corporation · schedule Prescription
Ministry pays: $1.1550 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60166 · Verify on the e-Formulary ↗ (DIN 02236876)
Source record
DIN 02236876: Alphagan
Raw flags: sec12=Y, sec3=Y
Item: 523600090; group id 614; item number 1581; lccId 00082; manufacturer id ALL
Source form: Oph Sol; strength: 0.2%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $3.7970; ministry $1.1550
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02236876
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60166
Interchangeable products
Brimonidine Tartrate Ophthalmic Solution · DIN 02515377 · $1.1550
Jamp-Brimonidine · DIN 02449226 · $1.1550
Med-Brimonidine · DIN 02507811 · $1.1550
Sandoz Brimonidine · DIN 02305429 · $1.1550
Shortage status: shortage reported ended 2026-09-10 (report last updated 2026-09-10); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02236876
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Brimonidine · DIN 02449226 · 0.2% · Oph Sol
Limited Use — Reason for Use code 171, 172, 387 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 171, 172, 387 required
Write on scriptLU code 171, 172, 387 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 171, 172, 387
Reason for Use code 171
As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 172
As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 387
For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Brimonidine · DIN 02449226
Manufacturer: Jamp Pharma Corporation; listing date 2023-05-31
Health Canada: Marketed since 2026-01-21 · brand JAMP BRIMONIDINE · ATC S01EA05 BRIMONIDINE · form Solution · route Ophthalmic · ingredients BRIMONIDINE TARTRATE 0.2 %/W/V · company Jamp pharma corporation · schedule Prescription
Jamp-Brimonidine: Formulary list price $1.1550/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.1550 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93504 · Verify on the e-Formulary ↗ (DIN 02449226)
Source record
DIN 02449226: Jamp-Brimonidine
Raw flags: sec12=Y, sec3=Y
Item: 523600090; group id 614; item number 1581; lccId 00082; manufacturer id JPC
Source form: Oph Sol; strength: 0.2%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.1550; ministry $1.1550
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02449226
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93504
Interchangeable products
Alphagan · DIN 02236876 · $1.1550
Brimonidine Tartrate Ophthalmic Solution · DIN 02515377 · $1.1550
Med-Brimonidine · DIN 02507811 · $1.1550
Sandoz Brimonidine · DIN 02305429 · $1.1550
Shortage status: resolved shortage (ended 2026-07-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02449226
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Med-Brimonidine · DIN 02507811 · 0.2% · Oph Sol
Limited Use — Reason for Use code 171, 172, 387 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 171, 172, 387 required
Write on scriptLU code 171, 172, 387 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 171, 172, 387
Reason for Use code 171
As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 172
As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 387
For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Med-Brimonidine · DIN 02507811
Manufacturer: Generic Medical Partners Inc.; listing date 2022-03-31
Health Canada: Marketed since 2021-11-26 · brand MED-BRIMONIDINE · ATC S01EA05 BRIMONIDINE · form Solution · route Ophthalmic · ingredients BRIMONIDINE TARTRATE 0.2 %/W/V · company Generic medical partners inc · schedule Prescription
Med-Brimonidine: Formulary list price $1.1550/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.1550 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99720 · Verify on the e-Formulary ↗ (DIN 02507811)
Source record
DIN 02507811: Med-Brimonidine
Raw flags: sec12=Y, sec3=Y
Item: 523600090; group id 614; item number 1581; lccId 00082; manufacturer id GMP
Source form: Oph Sol; strength: 0.2%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.1550; ministry $1.1550
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02507811
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99720
Interchangeable products
Alphagan · DIN 02236876 · $1.1550
Brimonidine Tartrate Ophthalmic Solution · DIN 02515377 · $1.1550
Jamp-Brimonidine · DIN 02449226 · $1.1550
Sandoz Brimonidine · DIN 02305429 · $1.1550
Shortage status: resolved shortage (ended 2022-11-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02507811
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Brimonidine · DIN 02305429 · 0.2% · Oph Sol
Limited Use — Reason for Use code 171, 172, 387 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 171, 172, 387 required
Write on scriptLU code 171, 172, 387 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 171, 172, 387
Reason for Use code 171
As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 172
As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 387
For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Brimonidine · DIN 02305429
Manufacturer: Sandoz Canada Inc.; listing date 2008-08-28
Health Canada: Marketed since 2008-02-08 · brand SANDOZ BRIMONIDINE · ATC S01EA05 BRIMONIDINE · form Solution · route Ophthalmic · ingredients BRIMONIDINE TARTRATE 0.2 % · company Sandoz canada incorporated · schedule Prescription
Sandoz Brimonidine: Formulary list price $1.1550/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.1550 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79097 · Verify on the e-Formulary ↗ (DIN 02305429)
Source record
DIN 02305429: Sandoz Brimonidine
Raw flags: sec12=Y, sec3=Y
Item: 523600090; group id 614; item number 1581; lccId 00082; manufacturer id SDZ
Source form: Oph Sol; strength: 0.2%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.1550; ministry $1.1550
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02305429
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79097
Interchangeable products
Alphagan · DIN 02236876 · $1.1550
Brimonidine Tartrate Ophthalmic Solution · DIN 02515377 · $1.1550
Jamp-Brimonidine · DIN 02449226 · $1.1550
Med-Brimonidine · DIN 02507811 · $1.1550
Shortage status: resolved shortage (ended 2026-03-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02305429
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Brimonidine Tartrate Ophthalmic Solution · DIN 02515377 · 0.2% · Oph Sol
Limited Use — Reason for Use code 171, 172, 387 required; Health Canada lists this DIN as Cancelled post market since 2026-06-19 — choose a marketed DIN from the same-category list.Discontinued 2026-06-19 · checked 2026-09-02
StatusLimited Use — Reason for Use code 171, 172, 387 required; Health Canada lists this DIN as Cancelled post market since 2026-06-19 — choose a marketed DIN from the same-category list.
Write on scriptLU code 171, 172, 387 (patient must meet the criteria below); Health Canada lists this DIN as Cancelled post market since 2026-06-19 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 171, 172, 387
Reason for Use code 171
As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 172
As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 387
For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Brimonidine Tartrate Ophthalmic Solution · DIN 02515377
Manufacturer: Teligent Canada Inc.; listing date 2022-01-31
Health Canada: Cancelled post market since 2026-06-19 · brand BRIMONIDINE TARTRATE OPHTHALMIC SOLUTION · ATC S01EA05 BRIMONIDINE · form Solution · route Ophthalmic · ingredients BRIMONIDINE TARTRATE 0.2 %/W/V · company Hikma canada limited · schedule Prescription
Brimonidine Tartrate Ophthalmic Solution: Formulary list price $1.1550/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.1550 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100476 · Verify on the e-Formulary ↗ (DIN 02515377)
Source record
DIN 02515377: Brimonidine Tartrate Ophthalmic Solution
Raw flags: sec12=Y, sec3=Y
Item: 523600090; group id 614; item number 1581; lccId 00082; manufacturer id TCI
Source form: Oph Sol; strength: 0.2%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.1550; ministry $1.1550
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02515377
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100476
Interchangeable products
Alphagan · DIN 02236876 · $1.1550
Jamp-Brimonidine · DIN 02449226 · $1.1550
Med-Brimonidine · DIN 02507811 · $1.1550
Sandoz Brimonidine · DIN 02305429 · $1.1550
Shortage status: discontinued (2025-04-01, reported by HIKMA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02515377
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2026-06-19 — choose a marketed DIN from the same-category list.
BRIMONIDINE TARTRATE & TIMOLOL MALEATE
All strengths: Limited Use — Reason for Use code 310, 393 required; same patient cost rules
Shared coverage and patient cost rules
StatusLimited Use — Reason for Use code 310, 393 required
Patient paysPatient pays: program not supplied; amount cannot be determined.
Other products in the same Health Canada class (S01E) — coverage varies; not interchangeable
- Acetazolamide (Acetazolamide): general benefit, Not a benefit
- Betaxolol (Betoptic S): general benefit
- Levobunolol (Betagan): general benefit
- Methazolamide (Neptazane): general benefit, Not a benefit
- Timolol (Timoptic-XE): general benefit, Not a benefit
- Bimatoprost (Lumigan): limited Use 171, 172, 387, Not a benefit
9 more in the class list below
Apo-Brimonidine-Timop · DIN 02375311 · 0.2% & 0.5% · Oph Sol-10mL Pk
Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-02
Write on scriptLU code 310, 393 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310
As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 393
For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Brimonidine-Timop · DIN 02375311
Manufacturer: Apotex Inc.; listing date 2022-12-21
Health Canada: Marketed since 2022-11-09 · brand APO-BRIMONIDINE-TIMOP · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.5 %, BRIMONIDINE TARTRATE 0.2 % · company Apotex inc · schedule Prescription
Apo-Brimonidine-Timop: Formulary list price $23.2900/unit (unit not stated in source; not the patient's cost)
Ministry pays: $23.2900 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86073 · Verify on the e-Formulary ↗ (DIN 02375311)
Source record
DIN 02375311: Apo-Brimonidine-Timop
Raw flags: sec12=Y, sec3=Y
Item: 523600115; group id 615; item number 1582; lccId 00156; manufacturer id APX
Source form: Oph Sol-10mL Pk; strength: 0.2% & 0.5%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $23.2900; ministry $23.2900
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02375311
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86073
Interchangeable products
Combigan · DIN 09857298 · $23.2900
Jamp Brimonidine/Timolol · DIN 02531704 · $23.2900
Shortage status: active shortage (reported 2025-12-16, estimated to end 2027-01-08, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02375311
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Brimonidine/Timolol · DIN 02531704 · 0.2% & 0.5% · Oph Sol-10mL Pk
Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-02
Write on scriptLU code 310, 393 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310
As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 393
For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Brimonidine/Timolol · DIN 02531704
Manufacturer: Jamp Pharma Corporation; listing date 2023-08-31
Health Canada: Marketed since 2023-07-21 · brand JAMP BRIMONIDINE/TIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients BRIMONIDINE TARTRATE 0.2 %/W/V, TIMOLOL (TIMOLOL MALEATE) 0.5 %/W/V · company Jamp pharma corporation · schedule Prescription
Jamp Brimonidine/Timolol: Formulary list price $23.2900/unit (unit not stated in source; not the patient's cost)
Ministry pays: $23.2900 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102081 · Verify on the e-Formulary ↗ (DIN 02531704)
Source record
DIN 02531704: Jamp Brimonidine/Timolol
Raw flags: sec12=Y, sec3=Y
Item: 523600115; group id 615; item number 1582; lccId 00156; manufacturer id JPC
Source form: Oph Sol-10mL Pk; strength: 0.2% & 0.5%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $23.2900; ministry $23.2900
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02531704
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102081
Interchangeable products
Apo-Brimonidine-Timop · DIN 02375311 · $23.2900
Combigan · DIN 09857298 · $23.2900
Shortage status: active shortage (reported 2026-03-12, estimated to end 2026-07-31, last updated 2026-05-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02531704
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Combigan · PIN 09857298 · 0.2% & 0.5% · Oph Sol-10mL Pk
Limited Use — Reason for Use code 310, 393 requiredOntario PIN; no Health Canada record under this code
Write on scriptLU code 310, 393 (patient must meet the criteria below)
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Health Canada record for this brand: DIN 02248347 (Marketed, 2023-12-13)
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72692
Check Health Canada brand DINPrivate plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310
As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 393
For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Savings card: innoviCares lists Combigan (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)1 brand, same coverage
Combigan · DIN 09857298
Manufacturer: Allergan Inc.; listing date 2008-08-28
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Health Canada record for this brand: DIN 02248347 (Marketed, 2023-12-13)
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72692
Ministry pays: $23.2900 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09857298)
Source record
DIN 09857298: Combigan
Raw flags: sec12=Y, sec3=Y
Item: 523600115; group id 615; item number 1582; lccId 00156; manufacturer id ALL
Source form: Oph Sol-10mL Pk; strength: 0.2% & 0.5%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $46.5800; ministry $23.2900
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09857298
Health Canada record for this brand: DIN 02248347 (Marketed, 2023-12-13)
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72692
Interchangeable products
Apo-Brimonidine-Timop · DIN 02375311 · $23.2900
Jamp Brimonidine/Timolol · DIN 02531704 · $23.2900
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=09857298
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered
Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL
Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE, TIMOLOL MALEATE
52:36 Other Eye, Ear, Nose and Throat Agents
· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 250mg · Tab
· 1 products · General benefit · strengths: 0.25% · Oph Susp
· 1 products · General benefit · strengths: 0.5% · Oph Sol
· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg · Tab
· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 0.25%, 0.5% · Oph Gellan Sol, Oph Sol
· 8 products · Listed, not a benefit (1),
Limited Use, codes 171, 172, 387 (7) · strengths: 0.03%, 0.01% · Oph Sol, Oph Sol-5mL Pk, Oph Sol-7.5mL Pk
· 1 products ·
Limited Use, codes 171, 172, 387 · strengths: 1% · Oph Susp
· 1 products ·
Limited Use, codes 310, 393 · strengths: 1% & 0.5% · Oph Susp-5mL Pk
· 5 products ·
Limited Use, codes 171, 172, 387 · strengths: 2% · Oph Sol
· 11 products ·
Limited Use, codes 310, 393 · strengths: 2% & 0.5% · Oph Sol, Oph Sol-0.2mL Pk
· 9 products ·
Limited Use, codes 171, 172, 387 · strengths: 0.005% · Oph Sol-2.5mL Pk
· 9 products ·
Limited Use, codes 310, 393 · strengths: 50mcg/mL & 5mg/mL · Oph Sol-2.5mL Pk
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:36
and 18 more
Availability
Brimonidine P · DIN 02301334
Shortage status: active shortage (reported 2026-09-08, estimated to end 2026-09-25, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02301334
Check this DIN againAlphagan · DIN 02236876
Shortage status: shortage reported ended 2026-09-10 (report last updated 2026-09-10); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02236876
Check this DIN againBrimonidine Tartrate Ophthalmic Solution · DIN 02515377
Shortage status: discontinued (2025-04-01, reported by HIKMA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02515377
Check this DIN againApo-Brimonidine-Timop · DIN 02375311
Shortage status: active shortage (reported 2025-12-16, estimated to end 2027-01-08, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02375311
Check this DIN againJamp Brimonidine/Timolol · DIN 02531704
Shortage status: active shortage (reported 2026-03-12, estimated to end 2026-07-31, last updated 2026-05-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02531704
Check this DIN again